← Back to headlines
Summit Therapeutics Reports Q2 GAAP EPS of -$0.28, Beats Estimates
Summit Therapeutics released its second-quarter financial results, reporting a GAAP EPS of -$0.28, which managed to beat analyst estimates by $0.01.
23 Jul, 20:25 — 23 Jul, 20:25
Sources
Showing 1 of 1 sources
Related Stories
Japan and U.S. Advance $550 Billion Investment Pact Focused on AI and Chips
1h ago
Anthropic Delays AI Startup IPO to Mid-October Amid Credit Facility Deal
2h ago
Trade Negotiations Stall as U.S. Halts Antitrust Cooperation With Canada
2h ago
Corporate Executives Across Various Sectors Sell Company Stock
2h ago